Detalhe da pesquisa
1.
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.
Lancet Oncol
; 25(1): 99-107, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38043558
2.
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 25(5): 563-571, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38621400
3.
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.
Lancet
; 401(10379): 821-832, 2023 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36774933
4.
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med
; 384(9): 829-841, 2021 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33657295
5.
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
N Engl J Med
; 384(14): 1289-1300, 2021 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33616314
6.
A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma.
BJU Int
; 133 Suppl 3: 57-67, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37986556
7.
Recent Advances in Alkenyl sp2 C-H and C-F Bond Functionalizations: Scope, Mechanism, and Applications.
Chem Rev
; 122(24): 17479-17646, 2022 12 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36240299
8.
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
Lancet Oncol
; 24(3): 228-238, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36858721
9.
Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management.
Eur J Nucl Med Mol Imaging
; 51(1): 295-303, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37592084
10.
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
Lancet Oncol
; 23(6): 768-780, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35489363
11.
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Lancet
; 397(10276): 797-804, 2021 02 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33581798
12.
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
Gynecol Oncol
; 167(3): 404-413, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36273926
13.
High-dose chemotherapy for relapsed germ cell tumours: outcomes in low-volume specialized centres.
BJU Int
; 130 Suppl 1: 5-16, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35355402
14.
Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer.
Int J Gynecol Cancer
; 32(4): 560-565, 2022 04 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34551895
15.
REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer.
Gynecol Oncol
; 161(2): 374-381, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33637349
16.
A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial.
Gynecol Oncol
; 163(1): 72-78, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34412908
17.
Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer.
BJU Int
; 128 Suppl 1: 18-26, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34622543
18.
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3.
Int J Gynecol Cancer
; 31(7): 949-958, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34103386
19.
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 21(5): 710-722, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32359490
20.
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Lancet Oncol
; 21(5): 699-709, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32305099